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Abstract
Background: Behçet’s disease (BD) significantly increases morbidity and mortality. BD mainly affects young adults
with a peculiar geographical distribution. It has been suggested that BD varies in its phenotypic expression in
different ethnic groups.
Methods: We investigated potential ethnicity-related differences relative to phenotype and prognosis of BD patients in
a French multiethnic country. We included 769 consecutive patients fulfilling the international criteria of classification
for BD, in the 3 largest ethnic groups of our cohort [European (n = 369), North African (n = 350) and sub Saharan African
(n = 50)]. Factors that affect prognosis were assessed by multivariate analysis.
Results: 535 (69.6%) patients were male and the median (IQR) age at diagnosis was of 30.9 (24.9-37.2) years. Sub
Saharan African BD patients had a higher frequency of CNS involvement (48% vs 32.3% vs 29.5%, p = 0 .035), a
higher rate of death (12% vs 6% vs 3.5%, p = 0.029) and a lower frequency of HLA B51 allele (29.4% vs 49.2% vs
55.8%, p = 0.009) compared to those from North Africa and Europe, respectively. Multivariate analysis showed that
male gender (HR: 5.01, CI: 1.51-16.65), cardiovascular involvement (HR: 2.24, CI: 1.15-4.36), and sub Saharan African
origin (HR 2.62 (0.98-6.97) were independently associated with mortality. The 15-year mortality rate was of 19%,
9% and 6% in sub Saharan African, North African and European BD patients, respectively (p = 0.015).
Conclusion: We reported ethnicity-related differences with respect to phenotype of BD. Sub Saharan Africans
patients exhibited a worse prognosis.
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Behçet’s disease (BD) or Adamantiades-Behcet's Disease
is a chronic, relapsing, vasculitis of unknown aetiology
characterized by mucocutaneous, ocular, articular, vascu-
lar, gastrointestinal, and central nervous system manifes-
tations [1]. BD significantly increases morbidity and
mortality. BD mainly affects young adults with a peculiar
geographical distribution, also named the “silk-road” –
corresponding to the ancient route between the Mediter-
ranean, the Middle East and the Far East. With the
exception of oral aphthosis, BD is characterized by con-
siderable phenotypic variation. Over the last 30 years, a
substantial body of knowledge has accumulated support-
ing a strong genetic underpinning in BD of the MHC-
related allele HLA-B5, which was later more specifically
linked to its predominant suballele HLA-B51 [2]. It has
been suggested that the disease varies in its phenotypic
expression in different races and in different countries.
Both environmental and genetic factors play a role in the
aetiology of the condition [3]. For instance, BD patients
from Asia exhibit a higher frequency of gastrointestinal in-
volvement compared to those from the Mediterranean
basin [4]. It has been reported that there is a greater risk
of ocular involvement in patients in Japan or Iran and a
lower risk of genital ulceration in most non-western coun-
tries [3]. However, most of the evidence supporting these
propositions arises from observational case series, which
are subject of many sources of bias. Moreover, to our
knowledge no data are available regarding BD in sub
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Saharan African population. The present study investi-
gated potential ethnicity-related differences relative to
phenotype and prognosis of BD patients in a French
multiethnic country. To this aim, we compared the
main features of BD, the outcome and the factors asso-
ciated with mortality in the 3 largest ethnic groups of our
cohort (i.e. European, North African and sub Saharan
African patients).
Patients and method
Patients
Clinical records of 769 consecutive patients fulfilling
the international criteria of classification for BD [5] were
analyzed. All patients were referred to and regularly
followed in the Internal medicine department of the
Pitié-Salpétrière university hospital, Paris, France be-
tween 1974 and 2010. For each patient, the following
data were collected: age at diagnosis of BD, gender, date
of criteria for BD, geographic origin, main features of
BD including mucocutaneous manifestations, ocular le-
sions, rheumatologic manifestations (athralgia, arthritis),
neurologic involvement and/or cardiovascular involve-
ment (venous, arterial and cardiac lesions). The number
of BD flare, treatment, outcome and causes of death
were recorded. 568 patients with BD were investigated
for HLA B5 typing. The 3 largest ethnic groups origi-
nated from Europe (n = 369), North Africa (n = 350) and
sub Saharan Africa (n = 50). Ethnicity was defined as the
country of origin of the patient’s parents and grandparents
and subjects were classified into 1 of the following defined
ethnic groups: European, North African (Moroccan,
Algerian, Tunisian, and Egyptian) and sub Saharan African.
We considered only the European, North African and sub
Saharan African patients, given the relatively small number
of patients in the other racial groups. The diagnosis of
neuro-BD was based on objective neurological symptoms
not explained by any other known disease or therapy asso-
ciated with neuroimaging findings suggestive of BD related
central nervous system (CNS) involvement and/or cerebro-
spinal fluid (CSF) findings showing aseptic inflammation.
Patients with non-parenchymal CNS involvement, or who
did not show any abnormality on neurological examination
or those without evidence of objective neurological in-
volvement (i.e. only headache or dizziness) were excluded.
The diagnosis of cardiovascular involvement included ven-
ous, arterial and cardiac lesions related to BD. Diagnosis of
venous thrombosis was based on imaging data: venous
doppler sonography, phlebography, cavography, computed
tomography angiography and/or angio-magnetic resonance
imaging (MRI). Diagnosis of arterial manifestations was
based on imaging data: doppler sonography, arteriography,
computed tomography angiography and/or angio-MRI.
Cardiac involvement (pericarditis, myocardiopathy, myocar-
dial infarction, endomyocardial fibrosis, thrombosis, valve
insufficiency and/or stenosis) was considered to be re-
lated to BD if it was contemporaneous with BD flares
and if other known causes of cardiac disease had been
excluded.
Literature review
We systematically screened the medical literature via
PubMed using the following keywords: “Behcet’s dis-
ease”, “Behcet’s syndrome”, “ethnology”, “ethnicity”, and
“epidemiology”. We only analyzed cases series published
after 1988 in English or in French. Studies focusing on
ethnicity related phenotype or prognosis differences in
adults BD patients were included. However, it should be
acknowledged that these different studies have different
approaches in case findings. Some studies were based on
epidemiological estimates while others describe patients
from tertiary referral centres and the latter were based
on questionnaire or population samples. The methodo-
logical differences can be substantial and might affect
the outcome of different cohorts.
Statistical analysis
Data are summarized as frequencies and percentages for
categorical variables. Quantitative variables are presented
as medians and 25th and 75th percentiles. Patients charac-
teristics were compared using χ2 tests (or χ2 tests with
Yates’s correction or Fisher’s exact test when required)
for categorical data and Kruskal-Wallis rank sum tests
for quantitative data. Survival was estimated using the
Kaplan-Meier method. Patients were censored at the
date of their last visit. Factors associated with the oc-
currence of death were assessed using a Cox propor-
tional hazard model. Proportional hazard assumptions
were checked. Hazard-ratios (HR) with their ninety-five
percent confidence intervals (95% CI) are presented as
a measure of association. All factors with P-value lower
than 0.05 in the univariable analysis were included in a
multiple Cox proportional hazard model. A model se-
lection based on p-value was then performed. All tests
were two-sided at the 0.05 significance level. Analyses
were performed using R 2.15.1 statistical package. This
study has been carried out in compliance with the
Helsinki declaration.
Results
Characteristics of BD patients
The main features of the 769 BD patients are summarized
in Table 1. The median (IQR) age at diagnosis was 30.9
(24.9-37.2) years with 535 (69.6%) male. Patients origi-
nated from Europe (47.9%), North Africa (45.5%) and sub
Saharan Africa (6.5%). The HLA B5 typing was positive in
51.4% of cases. Main clinical signs of BD included eye in-
volvement (65.9%), genital ulcerations (60.4%), articular
involvement (48.6%), cardiovascular involvement (42.6%)
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and central nervous system involvement (31.7%). The me-
dian number of BD’s flare was of 3 (2–5).
The comparison between main characteristics accord-
ing to ethnic origin of BD patients showed a higher fre-
quency of male in sub Saharan and North African
patients compared to those from Europe (78% and 78%
vs 52.3%, respectively). The male/female ratio in the
sub-Saharan and North African groups was of 3.5. There
was a higher frequency of CNS involvement (48% vs
32.3% vs 29.5%) (p = 0.035), a higher rate of death (12%
vs 6% vs 3.5%) (p = 0.029) and a lower frequency of HLA
B51 allele (29.4% vs 49.2% vs 55.8%) (p = 0.009) in pa-
tients from sub Saharan Africa compared to those from
North Africa and Europe, respectively. The time between
first symptoms and diagnosis of BD was not significantly
different according to ethnic groups (Table 1). There
were no significant differences regarding the 3 separated
periods (i.e. before 1990, between 1990 and 2000, and
after 2000) of management of BD according to the 3 eth-
nics groups.
Survival rate according to ethnic origin
The 5-, 10- and 15 year survival rate was of 90%, 87%
and 81% in sub Saharan African BD patients as com-
pared to 96%, 93% and 91% and 99%, 96% and 94% in
those from North Africa and Europe (p = 0.015), respect-
ively (Figure 1).
Factors associated with mortality
Comparison between alive and deceased patients showed
a higher proportion of men and of cardiovascular in-
volvement and a lower frequency of HLA B5 genotype
in the deceased group (Table 2). The analysis of factors
associated with mortality is summarized in Table 3. In
univariate analysis, there was no significant association
between mortality and oral ulceration, articular involve-
ment, central nervous system involvement, and eyes in-
volvement. Patients who died were younger (p = 0.002),
more frequently of male gender (p = 0.001), had a higher
frequency of cardiovascular involvement (p = 0.009), had
more frequently glucocorticosteroids (p = 0.013) and im-
munosuppressants use (p = 0.020), more frequently origi-
nated from sub Saharan Africa (p = 0.015) and had a lower
frequency of genital ulceration (p = 0.006). In multivariate
analysis (Table 3), male gender (OR: 5.01, CI: 1.51-16.65),
cardiovascular involvement (OR: 2.24, CI: 1.15-4.36) and
African sub-Saharan origin (OR: 2.62, CI: 0.98-6.97) were
independently associated with mortality.
Literature review
We found 11 manuscripts, with a total of 910 patients
that assessed ethnicity related phenotypic or prognosis
differences in BD [6-16]. Three of them [6,9,12] were ex-
cluded because two compared their patients’ characteris-
tics to data reported in the literature, and one was using
the same cohort of BD patients previously reported. We
analysed 8 studies (783 patients), over a period of 1988 to
2012, that have addressed ethnicity related differences ac-
cording to phenotype and outcome of BD [7,8,10,11,13-16].
The Table 4 summarized the main characteristics and con-
clusions of studies analysing ethnicity related differences in
BD.
Discussion
Ethnic origin is one of the factors that may modulate the
prevalence and expression of BD. Analysis of the litera-
ture showed that studies assessing ethnicity related dif-
ferences in BD are scarce and often derived from small
samples thus preventing clear conclusions. Herein, we
reported ethnicity-related differences with respect to
phenotype and prognosis of BD in a French multiethnic
country.
The comparison of our BD patients according to their
ethnic origin showed a higher frequency of male in sub
Saharan and North African patients as compared to
those from Europe. Similar to variations in the clinical
manifestations, gender distribution in BD patients varies
widely depends on their ethnic origin and country of
residence. For instance, the percentage of male BD
Table 1 Characteristics of Behçet’s disease according to
ethnic origin*
Parameters Europe Sub
saharan
Africa
North
Africa
p-
value
(n = 369) (n = 50) (n = 350)
Age at diagnosis
(years)
30.6
[24.9; 36.9]
32.21
[24.9; 40.7]
30.59
[24.5; 37.2]
0.55
Time between
first symptom
to diagnosis
of BD (years)
3.1 [0.2; 7.9] 1.9 [0.04; 7.6] 1.9 [0.04; 7.6] 0.059
Maler gender 193 (52.3) 39 (78) 273 (78) <0.0001
Genital ulceration 217 (58.81) 31 (62) 217 (62) 0.66
Articular
involvement
188 (51.09) 23 (46) 163 (46.7) 0.47
Ocular involvement 245 (66.4) 26 (53.06) 236 (67.43) 0.14
CNS involvement 108 (29.51) 24 (48) 112 (32.28) 0.035
CV involvement 152 (41.19) 27 (54) 149 (42.57) 0.22
HLAB51 163/292
(55.82)
10/34
(29.41)
119/242
(49.17)
0.009
Number of BD flares 3 [2;5] 3 [2;4.5] 3 [2;5] 0.81
Immunosuppressants 178 (48.24) 26 (52) 206 (58.86) 0.016
Glucocorticosteroids 239 (64.77) 33 (66) 238 (68) 0.66
Anticoagulation 27 (7.32) 2 (4) 20 (5.71) 0.63
Death 13 (3.52) 6 (12) 21 (6) 0.029
*Except where indicated otherwise values are the median, IQR or n, percentage.
CNS, central nervous system; BD, Behçet’s disease; CV, cardiovascular.
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patients in a recent study ranges from 27% in USA to
87% in Azerbaijan [17]. Male gender is a main factor as-
sociated with mortality in BD [18,19]. In our previous
study, 92.7% of the BD patients who died were of male
gender [19]. In multivariate analysis, male gender in-
creased by 5 times the odds of death. Male gender and a
younger age at onset have been previously reported to
markedly influenced disease expression and course of
BD [18]. Lastly, male patients tended to have more flare
of BD compared to female [19].
We observed ethnicity-related differences regarding
phenotype of BD. Our study shows a 1.6 times higher
frequency of CNS involvement among patients from sub
Saharan Africa as compared to those from North Africa
and Europe. Cardiovacular involvement tended to be
more frequent in sub-Saharan African patients but dif-
ference did not reach statistical significance. Arterial and
cardiac complications are less common than venous le-
sions in BD, occurring in 1 to 7% of patients [20]. The
concept of vasculo-Behçet’s has been adopted for cases
in which vascular complications are present and often
dominate the clinical feature that fit with the phenotype
of our sub Saharan African BD patients. The main
causes of death in BD included major vessel disease, and
central nervous system involvement [18,19]. The fre-
quency of CNS involvement in BD varies widely accord-
ing country and ranges from 3% in Iran to 34% in Saudi
Arabia [17]. The 48% rate of CNS lesions found in our
Figure 1 Survival curve of 679 patients with BD according to their ethnic origin (Europe vs sub-saharan Africa vs North Africa).
BD, Behçet’s disease.
Table 2 Comparative analysis between alive and
deceased BD patients
Parameters N Alive N Deceased
729 (n = 729) 40 (n = 40)
Age at diagnosis 724 30.6
[24.6; 37.19]
40 32.42
[27.0; 44.19]
Male sex 468 64.2% 37 92.5%
Genital ulcerations 448 61.45% 17 42.5%
Oral ulcerations 724 99.31% 40 100%
Articular
involvement
354 48.83% 20 50%
Ocular involvement 482 66.21% 25 62.5%
CNS involvement 229 31.67% 15 37.5%
Cardiovascular
involvement
301 41.29% 27 67.5%
Immunosuppressants 380 52.13% 30 75%
Corticosteroids 475 65.16% 35 87.5%
Anticoagulation 46 6.31% 3 7.5%
HLAB5* 281/538 52.23% 11/30 36.67%
Ethnicity
Europe 356 48.83% 13 32.5%
Sub Saharan Africa 44 6.04% 6 15%
North Africa 329 45.13% 21 52.5%
CNS, central nervous system, BD, Behçet's disease.
*HLAB5 was available for 538 out of 729 patients.
Except where indicated otherwise values are the median, IQR.
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sub Saharan African BD patients was clearly higher than
the frequency observed in Saudi Arabia. Although not
independently associated with mortality, CNS involve-
ment accounted for 12% of deaths in our previous study
[19]. In large studies addressing neurologic disease of
BD, the mortality rate range between 5.5 and 20%
[21,22]. The median period until death was of 4 years
after neurological onset [21]. It was previously reported
that BD has diverse clinical expression in various geo-
graphical areas. The pathergy reaction is considered
highly sensitive and specific for BD in patients from
Turkey and Japan, yet is frequently negative in patients
from Western countries [23], or gastrointestinal (GI) in-
volvement, which occurs in about one-third of patients
from Japan, but rarely in Mediterranean countries.
O’Neill et al. [24], described regional differences regard-
ing several clinical manifestations of BD. They reported
that BD patients from Middle Eastern countries and the
Mediterranean basin generally have less widespread
disease compared with patients from Western countries
(i.e. UK and USA), manifested by lower rates of arth-
ritis, vascular problems, and CNS abnormalities [24].
The HLA B5 allele was two times less frequently
found in sub Saharan African BD patients as compared
to those from Europe and North Africa and with the
Table 3 Factors associated with mortality in Behçet’s
disease
Univariate
analysis
Multivariate
analysis
Parameters HR (CI 95%) p HR (CI 95%) P
Age at diagnosis 1.04 (1.01-1.07) 0.002 1.05 (1.02-1.08) 0.0007
Male gender 6.87 (2.1-22.3) 0.001 5.01 (1.51-16.65) 0.0085
Ethnic origin
Europe 1 0.015
North Africa 1.93 (0.96-3.85)
Sub Saharan Africa 3.75 (1.43-9.88) 2.62 (0.98-6.97) 0.015
HLA B5 0.54 (0.26-1.13) 0.10
Oral ulcerations 0.54 (0.1-2.2) 0.39 0.41 (0.22-0.78) 0.0069
Genital ulcerations 0.42 (0.22-0.79) 0.006
Ocular involvement 0.81 (0.43-1.54) 0.53
CNS involvement 1.05 (0.55-2) 0.88
Articular
involvement
0.8 (0.43-1.54) 0.49
Cardiovascular
involvement
2.43 (1.25-4.7) 0.009 2.24 (1.15-4.36) 0.0184
Corticosteroids 3.3 (1.29-8.43) 0.013
Immunosuppressants 2.35 (1.15-4.8) 0.020
CNS, central nervous system, BD, Behçet's disease.
Table 4 Literature review of studies that have addressed ethnycity related differences according to phenotype and
outcome of BD [7,8,10,11,13-16]
First
author
Country Year of
publication
Nb of
patients
Ethnicity Observations*
Wechsler Paris (France) 1988 196 French Men (n = 36) and North African men
(n = 160).
No significant difference
Zouboulis Allemangne 1997 196 Allemands (n = 82), Immigrés Turques
(n = 86) patients originaires de pays
étrangers autres (n = 28)
Plus d’atteintes oculaires chez les patients
du Sud-Est de l'Europe (Italie, Gèce) et de
Turquie. 25% des patients avec évolution
défavorable, 3 décès, tous Allemands.
Zouboulis Germany 1997 196 German (n = 82), Turkish immigrants (n = 86),
and patients from other foreign countries
(n = 28)
Ocular disease is more frequent in
South-Eastern European patients and
in Turkish immigrants.
Muhaya Kurume (Japan)
London (England)
2000 54 Japanese (n = 35) and British (n = 19)
(including: 12 caucasians, 5 Middle Eastern,
1 African, 1 Asian)
Kurume patients have more active anterior
uveitis and more posterior uveitis than
London patients.
Krause Tel Aviv (Israel) 2001 100 Jewish patients (n = 66) (most of them
originated from Iran/Iraq, Turkey and North
African countries) and Arabic patients (n = 34)
Arabic patients have more severe ocular
diseases. Jewish patients from North African
countries have higher disease severity score.
Kotter Tübingen
(Germany)
2004 65 German (n = 32) and Turkish descents (n = 33) No significant difference
Rozenbaum Northern area of
Israel
2007 53 Arabs (n = 30) and Druzes (n = 23) Higher frequency of uveitis, of deep vein
thrombosis, and of CNS involvement, and a
higher global severity score in Arabs.
Mahr Seine-Saint-Denis
County (France)
2008 79 European patients (n = 19) and non-
European patients (n = 60).
No significant difference
Mohammad Skåne (Sweden) 2012 40 Swedish ancestry (n = 12) and non-Swedish
ancestry (28/40, 70%) [Middle East (n = 15),
Africa (n = 2), East Asia (n = 2); Turkey (n = 2),
Central and Eastern Europe (n = 6)]
No significant difference
*Difference with respect to phenotype or outcome of BD. CNS, central nervous system.
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overall prevalence of HLA B5 allele usually reported in
BD studies [25]. Large association analysis studies have
reported that HLA B51 is carried by one-to two-thirds
of BD patients and increases the risk of BD development
by 6 [25]. Authors have suggested that HLA B51 positive
and negative BD patients differed in that the former
more frequently developed eye involvement [26] or
sometimes CNS involvement [1] and the latter more
commonly thrombophlebitis. However, based on two re-
cent large meta-analyses, it has been shown that no real
association exists between HLA-B51 positivity and the
frequency of CNS involvement [25]. In contrast, uveitis,
genital ulcerations and skin lesions were more frequent
in BD patients carrying this allele. However, whether BD
carriers of HLA-B51 allele exhibit a more severe disease
course is still unknown.
The most original finding of our study is that sub
Saharan African BD patients had up to 3 times higher
mortality compared to North African and European pa-
tients. Their 15-year mortality rate was of 20% which
was much higher than the 5-10% usually found in large
series of BD patients [18,19]. The sub Saharan African
group was independently associated with a poor out-
come as well as male gender and cardiovascular involve-
ment in our BD patients. These data has, to the best of
our knowledge, never been described in the literature.
We suggest that a particular attention should be given
to sub Saharan African patients in BD. Krause et al. [8]
have described the influence of ethnic origin on clinical
expression and disease severity in Israeli patients. They
studied 100 patients fulfilling International Study Group
criteria for BD including 66 Jewish and 34 Arabic pa-
tients. The 3 largest ethnic groups of Jewish patients
were from Iran/Iraq (n = 21), Turkey (n = 12), and North
Africa (n = 21) countries. Arabic patients had more se-
vere ocular disease with significantly higher rate of pos-
terior uveitis (20.6 vs 4.6%). In the 3 most common
Jewish ethnic groups, patients form Iran/Iraq disclosed
higher rate of folliculitis (61.9 vs and 28.6%). Jewish pa-
tients from North African countries had higher rate of
ocular disease and disease severity score was signifi-
cantly higher in this population. Zouboulis et al. [16],
analysed the clinical features of 196 BD patients
[German (n = 82), Turkish immigrants (n = 86) or immi-
grants from other countries (n = 28)]. They found a higher
rate of ocular disease in South-Eastern European patients
(Italy and Greece) compared to South-Western and North
European patients. Frequency of ocular lesions was also
more frequent in Turkish patients compared to German.
We acknowledge some limitations in the current
study. Our analysis was performed as a retrospective
review. Socioeconomic differences may exist in our
study population, especially between European and African
(i.e. North or sub Saharan) patients. However, the time
between first symptoms to BD diagnosis was equivalent be-
tween groups. Access to medical system does not seem to
significantly account for the differences observed because
the French social security system covers all medical care.
One can hypothesize that genetic factors (i.e. HLA B 51
and/or others) may be involved in ethnic differences with
respect to phenotype and outcome of BD. We were not
able to collect country of birth of BD patients in a compre-
hensive manner in order to provide some insight into en-
vironment versus genetic influences.
In conclusion, in a French multiethnic country, sub
Saharan African BD patients exhibited a worse prognosis.
They displayed a higher frequency of CNS involvement
and trend toward higher cardiovascular involvement com-
pared to BD patients from Europe or North Africa. Their
15-year mortality rate reached 20% which is 3 times
higher than the overall mortality in BD. Taken together,
these data suggest that a particular attention should be
given to sub Saharan African BD patients.
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